Obesity & Overweight
Conditions
Brief summary
As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.
Interventions
PROCEDUREPharmacological or surgical treament of obesity
Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.
Sponsors
Université Catholique de Louvain
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 65 years * Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment. * Good physical and mental health, enabling informed consent. * French speaker
Exclusion criteria
* Legal protection * Pregnancy or breastfeeding * History of bariatric surgery (except gastric banding, provided it was removed more than five years ago). * Acute or progressive chronic disease * Alcohol consumption of more than 20 g/day * Inflammatory bowel disease; * Digestive autonomic diabetic neuropathy. * Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3). * Following a vegan or gluten-free diet or being lactose intolerant. * Fibre consumption \>30 g/day * Recent change in antidiabetic medication within the past 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters. | Throughout the entire study, aproximately during 5 years | The percentage of excessive weight loss after treatment will be correlated with * Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0) * Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test) * Biological parameters |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Binge Eating Disorder. | Throughout the entire study, aproximately during 5 years | Evaluation of eating disorders using the Binge Eating Scale (BES). |
| Food Addiction. | Throughout the entire study, aproximately during 5 years | Evaluation of food addiction will be performed using modified Yale Food Addiction Scale 2.0. |
| Eating attitudes | Throughout the entire study, aproximately during 5 years | Eating patterns and habits will be screened using the Eating Attitude Test 26 |
| Cognitive flexibility. | Throughout the entire study, aproximately during 5 years | Neuropsychological evaluation of cognitive flexibility will be performed with the Trail Making Test |
| Impulsivity. | Throughout the entire study, aproximately during 5 years | Impulsivity will be assessed using the Barrat Impulsiveness Scale (BIS) |
| Self-reported quality of life. | Throughout the entire study, aproximately during 5 years | Self-reported quality of life will be assessed using the QOLOD (Quality of Life, Obesity and Dietetics) |
| Obesity. | Throughout the entire study, aproximately during 5 years | Weight will be measured at each timepoint |
| Physical activity. | Throughout the entire study, aproximately during 5 years | Weekly physical activity will be reported with the Godin Leisure Time Exercise Questionnaire (GLTEQ) |
| Food intake. | Throughout the entire study, aproximately during 5 years | Eating habits will be recorded with a Food Frequency Questionnaire (FFQ) |
| Blood samples | Throughout the entire study, aproximately during 5 years | Blood samples will be collected and processed for metabolomic analyses. |
| Fecal sample | Throughout the entire study, aproximately during 5 years | Feces samples will be collected and processed to evaluation gut-microbiota composition |
Countries
Belgium
Contacts
CONTACTPr Amandine Everard, Professor
CONTACTYannick Deswysen, Doctor
STUDY_DIRECTORAmandine Everard, Professor
Université Catholique de Louvain
Outcome results
None listed